Slide 1: Unlocking the world of Live Micro Imaging (LMI) technology
Unlocking the world of Live Micro Imaging (LMI) technology
Slide 2: Technology and IP
& Technology and IP * Business model & Pentax flexible endo-microscope & Rigid endo-microscope and in-vivo research opportunities & Financials (cee
Slide 3: Technology Enables
Technology Enables * WMiniaturised devices for:in vivo examination of inter body tissues * Microscopic subcellular view (~1000x) * Non-invasive, real-time imaging Human Colonic Mucosa
Slide 4: Patented Fibre Optic Confocal System
Patented Fibre Optic sonfo: al Sy: Scan . mechanism aS Beam a, ze Objective Optical fibre lens Imaging plane Tissue (treet (©ptiscan
Slide 5: Patent Portfolio
Patent Portfo Patented Technologies Jurisdiction * Optical Fibre Confocal - 2 patent families USA, Canada, Australia, Europe y/Aug 2009 * Scan Miniaturisation - 4 patent families UK, Australia July 2018 Under Examination in USA, Germany, Japan * Pentax Endoscope - 10 patent families Filed for all ma
Slide 6: Business Model
Business M Statement of Strategic Dir Optiscan will pursue a focussed commercialisation of its Intellectual Property, enhancing it and bringing it to market through partners with leading positions in their respective markets Optiscan must partner to achieve full commercialisation of clinical instrum
Slide 7: Flexible Endoscopes, Medical Instruments, Research Confocal
Flexible Endoscopes Endoscopes ies Medical Instruments PENTAX Research Confocal eG 5
Slide 8: Licensing of Intellectual Property — royalties and up front payments
Licensing of Intellectual Property — royalties and up front payme ° Royalties — e.g.s * 5—10% exclusive license to Pentax for flexible endoscopes * 0.5-— 1.4% non-exclusive to various manufacturers for research confocal microscopes * Up front payments from partners — e.g. * US$3.33M initial payment
Slide 9: Occurrences expected
Occurren Successful exhibition at Digestive Diseases Week™ fo Receipt of final payment from Pentax Jun—Oct 2003 ¥ Completion of engineering for Pentax sales release Up to Pentax* Pentax initial order(s) Up to Pentax™* v Partnership for rigid endo-microscopes Partnership for in-vivo research confocal
Slide 10: Pentax's Position in Flexible Endoscopes
Pentax’s Position in Flexi The global flexible endoscope market is ~US$850Mpa Olympus is market leader, Pentax is number 2: Pentax profit contribution from their flexible endoscope business is significantly greater than from their camera business Extensive salesforce and service infrastructure for f
Slide 11: Confocal microscope scanner
confocal microscope scanner Illumination and video processor unit Imaging System Confocal (ISC) control boxes ann — ——— (©ptiscan
Slide 12: Pentax have already paid US$10M to develop technology
Pentax have already paid US$10M to develop technology. and ébtain an i 6 endoscopy Initial order received from Pentax in early October for — * 20 1ISC control boxes * 25 miniaturised confocal microscope scanners * Value A$1.4M Contribution from initial and future orders derived from * Gross margin o
Slide 13: Trials and Applications
Trials and A plica Clinical endo-microscope trials have commenced in three locations ° Cabrini Hospital, Melbourne, Austral * University Hospital, Mainz, Germany * Kyushu University Hospital, Fukuoka, Japan Trials are due to commence soon in USA (2 sites) and France Physician response has been very
Slide 14: Higher magnification than existing endoscopes
magnification than existin ing «¢ Normal view, E LAER Close up view sy Assoc Prof Ralf Kiess' many
Slide 15: Investigating doctors are differentiating normal from neoplastic tissue
Investigating doctors are differentiating normal from neoplastic tissue ee, AON ONO Normal colonic mucosa LO ge . Roume, Australi * Determined by confirmatory biopsy } CC reTerlrlrlrrrrrrr———~—”—”—”— Ss
Slide 16: Pentax's Market Development
Pentax’s Market Devel Exhibit at major international congres Week : Hold development advisory meeting with leading doctors global Undertake trials at selected leading teaching hospitals Market and sell through their flexible endoscope salesforce initially targeting * Opinion leaders with well aligne
Slide 17: Rigid Endo-Microscope Opportunities
Rigid Endo-Microscope oJ At an estimated US$720M pa the gl scope equipment market is somewhat smaller and is more e fragmented the the flexible endoscope market = Only modest levels of Optiscan R&D expenditure required to realise opportunities due to miniaturisation already achieved for Pentax Optis
Slide 18: Research opportunities
Research oppo Research markets for confocal microscopes are sizeable at approx US$375M pa Optiscan’s miniaturisation creates new in-v. ch applications with the potential to increase market demand for confocal microscopes Sales channels and applications support are important for success Optiscan is a
Slide 19: Financial results
* Operating revenues * Total expenses * R&D expense percentage ° Once off Restructuring costs $0.79M - * Net loss after tax $3.43M $2.50M * Cash $15.12M $15.98M * Other Assets $ 4.20M $ 6.06M * Liabilities $ 3.13M $ 2.45M (cee
Slide 20: Financials
Financia Current monthly cashburn ~$0.5M Pentax volumes the key to revenue * Project Committee base line expectation is for sales rates at the end of year 3 of : * 120 - 160 pa ISC systems (1 scope and control box) * 60 - 160 pa additional scopes* ® Significant upside available from compelling effic
Slide 21: Strong technology, solid cash position
& & Strong technology Solid cash position Focussed management delivering milestones Flexible endo-microscope commercialisation starting 2004 ¢ Large global market and excellent partner in Pentax * Solid base line with significant upside available Significant additional opportunities ¢ Rigid endo-mic
Slide 22: Optiscan Imaging Ltd
Optiscan Imaging Ltd 15-17 Normanby Road, Notting Hill, Vic. 3168, Australia ph: +61 3 9538 3333; fax: +61 3 9562 7742 www.optiscan.com (cee